UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.
|Videos|September 17, 2020
A 73-Year-Old Male With Urothelial Carcinoma
Author(s)Neeraj Agarwal, MD
Neeraj Agarwal, MD, reviews the case of a 73-year-old man with unresectable, locally advanced urothelial carcinoma and discusses latest data and treatment approaches.
Advertisement
Case Overview: A 73-Year-Old Male With Urothelial Carcinoma
Initial presentation
- A 73-year-old man presents with LUTS with intermittent hematuria
- PMH: HTN, well-controlled on an ARB; mild hepatic and renal impairment
- PE: distension of bladder; slow flow on voiding
Clinical workup
- Labs: Hb 11.4 g/dl, WBC 3.5 x 109/L, AST and ALT: ~4x ULN, CrCl: 35 mL/min; others WNL
- Cystoscopy: showed a 2.6 cm mass around the neck of the bladder
- TURBT was performed; transition cell carcinoma of the urothelium, with tumor invading the perivesical tissue
- Chest/abdomen/pelvic CT scan: large bladder mass, evidence of multiple regional lymph nodes involved (perivesical and sacral), and a 2.3 cm mass in the left upper lobe
- Stage IIIB; ECOG PS 1
Treatment
- Patient received 6 cycles of carboplatin + gemcitabine; achieved partial response
- CT abdomen/pelvis showed decrease size in bladder mass, nodal findings mildly improved, no evidence of new disease
- Initiated avelumab 10 mg/kg IV q2W as maintenance therapy
Advertisement
Related to this article
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
4
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
5